COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors

Cancer. 2021 Jun 1;127(11):1937-1938. doi: 10.1002/cncr.33432. Epub 2021 Mar 15.

Authors

Alejandro Morales-Ortega¹, Jaime García de Tena², Begoña Frutos-Pérez¹, Beatriz Jaenes-Barrios³, Ana Isabel Farfán-Sedano¹, Miguel Ángel Canales-Albendea⁴, David Bernal-Bello¹

Affiliations

¹ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
² Department of Medicine, Universidad de Alcalá, Madrid, Spain.
³ Castilla La Nueva Primary Health Care Center, Madrid, Spain.
⁴ Department of Hematology, Hospital Universitario La Paz, Madrid, Spain.

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19*
Hematologic Neoplasms* / drug therapy
Humans
Protein Kinase Inhibitors / adverse effects
Risk Factors
SARS-CoV-2

Substances

Protein Kinase Inhibitors